BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23259501)

  • 1. Number of rare germline CNVs and TP53 mutation types.
    Silva AG; Achatz IM; Krepischi AC; Pearson PL; Rosenberg C
    Orphanet J Rare Dis; 2012 Dec; 7():101. PubMed ID: 23259501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
    Ariffin H; Hainaut P; Puzio-Kuter A; Choong SS; Chan AS; Tolkunov D; Rajagopal G; Kang W; Lim LL; Krishnan S; Chen KS; Achatz MI; Karsa M; Shamsani J; Levine AJ; Chan CS
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15497-501. PubMed ID: 25313051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
    Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
    JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours.
    Aury-Landas J; Bougeard G; Castel H; Hernandez-Vargas H; Drouet A; Latouche JB; Schouft MT; Férec C; Leroux D; Lasset C; Coupier I; Caron O; Herceg Z; Frebourg T; Flaman JM
    Eur J Hum Genet; 2013 Dec; 21(12):1369-76. PubMed ID: 23612572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.
    Shlien A; Tabori U; Marshall CR; Pienkowska M; Feuk L; Novokmet A; Nanda S; Druker H; Scherer SW; Malkin D
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11264-9. PubMed ID: 18685109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
    Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
    BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the
    Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
    JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation patterns of candidate genes regulated by thymine DNA glycosylase in patients with TP53 germline mutations.
    Fortes FP; Kuasne H; Marchi FA; Miranda PM; Rogatto SR; Achatz MI
    Braz J Med Biol Res; 2015 Jul; 48(7):610-5. PubMed ID: 25945745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
    Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
    Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Common Germline
    Jeffers JR; Pinto EM; Rehg JE; Clay MR; Wang J; Neale G; Heath RJ; Lozano G; Lalli E; Figueiredo BC; Pappo AS; Rodriguez-Galindo C; Chen W; Pounds S; Ribeiro RC; Zambetti GP
    Cancer Res; 2021 May; 81(9):2442-2456. PubMed ID: 33637564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
    Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
    Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis.
    Light N; Layeghifard M; Attery A; Subasri V; Zatzman M; Anderson ND; Hatkar R; Blay S; Chen D; Novokmet A; Fuligni F; Tran J; de Borja R; Agarwal H; Waldman L; Abegglen LM; Albertson D; Finlay JL; Hansford JR; Behjati S; Villani A; Gerstung M; Alexandrov LB; Somers GR; Schiffman JD; Rotter V; Malkin D; Shlien A
    Nat Commun; 2023 Jan; 14(1):77. PubMed ID: 36604421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
    Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
    Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.